HUP9801250A2 - Makrociklusos 3,4-bisz(3,3'-indolil)-pirrolin-2,5-dion-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Makrociklusos 3,4-bisz(3,3'-indolil)-pirrolin-2,5-dion-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9801250A2
HUP9801250A2 HU9801250A HUP9801250A HUP9801250A2 HU P9801250 A2 HUP9801250 A2 HU P9801250A2 HU 9801250 A HU9801250 A HU 9801250A HU P9801250 A HUP9801250 A HU P9801250A HU P9801250 A2 HUP9801250 A2 HU P9801250A2
Authority
HU
Hungary
Prior art keywords
atom
alkyl
carbon
macrocyclic
indolyl
Prior art date
Application number
HU9801250A
Other languages
English (en)
Inventor
William F. Heath
Michael R. Jirousek
John H. Mcdonald
Christopher J. Rito
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP9801250A2 publication Critical patent/HUP9801250A2/hu
Publication of HUP9801250A3 publication Critical patent/HUP9801250A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgyát (I) általánős képletű vegyületek, azelőállításűkra szőlgáló eljárás és az azőkat tartalmazógyógyszerkészítmények képezik. Az (I) általánős képletben W jelentése őxigénatőm, kénatőm vagy NH képletű csőpőrt, R1 jelentése hidrőgénatőm, halőgénatőm, 1-4 szénatőmős alkil-,hidrőxil-, 1-4 szénatőmős alkőxi-, halő-alkil-, nitrőcsőpőrt, -NH-(1-4szénatőmős)-alkil-, -N-di(1-4 szénatőmős)-alkil- vagy -NHCO-(1-4szénatőmős)-alkil általánős képletű csőpőrt. R2 jelentése hidrőgénatőm, CH3CO-, NH2 képletű csőpőrt vagyhidrőxilcsőpőrt, Z jelentése -(CH2)p- vagy -(CH2)p-O-(CH2)p- általánős képletű csőpőrt, R8 jelentése -NH(CF3) vagy -N(CF3)(CH3) képletű csőpőrt, m jelentése 0, 1, 2 vagy 3, és p jelentése 0, 1 vagy 2. A találmány szerinti vegyületek prőtein-kináz C gátló hatásúak. ŕ
HU9801250A 1995-03-30 1996-03-28 Macrocyclic 3,4-bis(3,31-indolyl)-pyrrole-2,5-dione derivatives, process for their preparation and pharmaceutical compositions containing them HUP9801250A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/413,735 US5624949A (en) 1993-12-07 1995-03-30 Protein kinase C inhibitors

Publications (2)

Publication Number Publication Date
HUP9801250A2 true HUP9801250A2 (hu) 1998-09-28
HUP9801250A3 HUP9801250A3 (en) 1998-12-28

Family

ID=23638401

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801250A HUP9801250A3 (en) 1995-03-30 1996-03-28 Macrocyclic 3,4-bis(3,31-indolyl)-pyrrole-2,5-dione derivatives, process for their preparation and pharmaceutical compositions containing them

Country Status (16)

Country Link
US (10) US5624949A (hu)
EP (1) EP0735038A1 (hu)
JP (1) JPH11507327A (hu)
KR (1) KR100319945B1 (hu)
CN (1) CN1093767C (hu)
AU (1) AU701988B2 (hu)
CA (1) CA2216535C (hu)
CZ (1) CZ286301B6 (hu)
EA (1) EA000598B1 (hu)
HU (1) HUP9801250A3 (hu)
MX (1) MX9707431A (hu)
NO (1) NO309271B1 (hu)
NZ (1) NZ305276A (hu)
PL (1) PL183600B1 (hu)
TR (1) TR199701073T1 (hu)
WO (1) WO1996030048A1 (hu)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
IL111850A (en) * 1993-12-07 2002-11-10 Lilly Co Eli 3, 4 - Bite (indolyl) from cyclic amides that inhibit kinase C protein, their preparation and boils that contain
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
ES2145978T3 (es) * 1995-11-20 2000-07-16 Lilly Co Eli Intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n'.
TW403754B (en) * 1995-11-20 2000-09-01 Lilly Co Eli Protein kinase c inhibitor
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
KR20000065137A (ko) * 1996-05-01 2000-11-06 미시시피 스테이트 유니버시티 할로-치환된 단백질 키나제 c 억제제
CZ350098A3 (cs) * 1996-05-01 1999-11-17 Eli Lilly And Company Způsob léčení neoplasie
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
EP0825190A1 (en) * 1996-08-23 1998-02-25 Eli Lilly And Company Synthesis of bisindolymaleimides
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US6040152A (en) * 1996-12-31 2000-03-21 National Jewish Medical And Research Center Method and assay for regulation of T cell proliferation
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
AU1392299A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Therapeutic treatment for chronic myeloid leukemia and acute lymphoid leukemia
CA2227688C (en) 1998-01-16 2007-07-31 James W. Critchfield Methods and compositions for inhibition of viral replication
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6291446B1 (en) * 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
WO1999047522A1 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
DE60118935D1 (de) * 2000-04-24 2006-05-24 Univ Yale New Haven Dna & protein bindende miniatur proteine
US20020048581A1 (en) * 2000-07-18 2002-04-25 King George L. Modulation of nitric oxide synthase by PKC
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
BR0116468A (pt) * 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
ES2245994T3 (es) 2000-12-08 2006-02-01 Ortho-Mcneil Pharmaceutical, Inc. Compuestos macro-heterociclicos utilizados como inhibidores de quinasa.
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US6559299B2 (en) * 2001-03-29 2003-05-06 Merck & Co., Inc. Preparation and isolation of indolocarbazole glycosides
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
GB0125658D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Medicaments
EP1790353A1 (en) * 2001-12-29 2007-05-30 Novo Nordisk A/S Combined use of a GLP-1 compound and a modulator of diabetic late complications
CA2484797A1 (en) * 2002-05-06 2003-11-13 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
BR0311821A (pt) 2002-06-05 2005-04-05 Janssen Pharmaceutica Nv Derivados de bisindolil-maleimid como inibidores de cinase
AU2003240517A1 (en) * 2002-06-05 2003-12-22 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
CN1832940A (zh) * 2003-06-13 2006-09-13 詹森药业有限公司 用作激酶抑制剂的取代的吲唑基(吲哚基)马来酰亚胺衍生物
JP4928261B2 (ja) 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
CA2526284C (en) 2003-06-25 2014-11-18 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
US9421175B2 (en) * 2004-03-17 2016-08-23 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
EP1749029B1 (en) 2004-05-27 2011-03-09 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20080096923A1 (en) * 2004-07-23 2008-04-24 Aniz Girach Methods For Diagnosing And Treating Diabetic Microvascular Complications
NZ553409A (en) 2004-10-12 2010-04-30 Crucell Holland Bv Binding molecules for treatment and detection of acute myeloid leukaemia
US8106170B2 (en) 2004-11-11 2012-01-31 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
US20070281988A1 (en) * 2004-12-20 2007-12-06 Cameron Norman E Combination Therapy for Vascular Complications Associated with Hyperglycemia
EP1877424A4 (en) * 2005-04-11 2010-09-29 Pharmagap Inc INHIBITORS OF PROTEIN KINASES AND USES THEREOF
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP2103623A3 (en) * 2005-07-25 2009-12-16 Intermune, Inc. Novel macrocyclic inhibitors of Hepatitis C virus replication
WO2007033374A2 (en) 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
EP1940411A4 (en) * 2005-09-29 2008-10-29 Janssen Pharmaceutica Nv MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
WO2007106400A2 (en) * 2006-03-10 2007-09-20 Janssen Pharmaceutica, N.V. Pyridine-containing macroheterocylic compounds as kinase inhibitors
CA2646316C (en) * 2006-03-15 2016-05-24 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
DK2395018T3 (en) * 2006-06-06 2016-04-25 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
KR20210044318A (ko) 2006-06-06 2021-04-22 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
AU2007293662B2 (en) 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
BRPI0716983B8 (pt) 2006-09-07 2021-05-25 Crucell Holland Bv anticorpo humano isolado, ou fragmento de ligação ao antígeno do mesmo,capaz de reconhecer e se ligar a um epítopo da subunidade ha2 da proteína hemaglutinina de influenza (ha), molécula de ácido nucleico e composição farmacêutica.
BRPI0811020A2 (pt) * 2007-05-03 2015-07-21 Intermune Inc Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral.
AU2008251425A1 (en) * 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
WO2009045291A2 (en) 2007-09-28 2009-04-09 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
US20090130195A1 (en) 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
EA201071034A1 (ru) * 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8470327B2 (en) 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors
CN110300584A (zh) 2016-12-19 2019-10-01 克罗马德姆公司 治疗色素沉着过度病症的方法
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
US11590131B2 (en) 2017-07-28 2023-02-28 Applied Therapeutics, Inc. Compositions and methods for treating galactosemia
KR20230005944A (ko) 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
SK278989B6 (sk) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
PT93947B (pt) * 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
MX9201643A (es) * 1991-04-11 1992-10-01 Schering Corp Agentes contra tumores y anti-psoriasicos.
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5344926A (en) * 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
PH30300A (en) * 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
DE69418978T2 (de) * 1993-12-07 1999-10-28 Lilly Co Eli Synthese von Bisindolylmaleimiden
IL111850A (en) * 1993-12-07 2002-11-10 Lilly Co Eli 3, 4 - Bite (indolyl) from cyclic amides that inhibit kinase C protein, their preparation and boils that contain
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
TW403754B (en) * 1995-11-20 2000-09-01 Lilly Co Eli Protein kinase c inhibitor

Also Published As

Publication number Publication date
CN1185742A (zh) 1998-06-24
TR199701073T1 (xx) 1998-02-21
NO309271B1 (no) 2001-01-08
AU701988B2 (en) 1999-02-11
US5739322A (en) 1998-04-14
CA2216535A1 (en) 1996-10-03
US5696108A (en) 1997-12-09
JPH11507327A (ja) 1999-06-29
CZ286301B6 (cs) 2000-03-15
US5621098A (en) 1997-04-15
KR100319945B1 (ko) 2002-03-08
NO974453D0 (no) 1997-09-26
US5780461A (en) 1998-07-14
CZ305197A3 (cs) 1998-05-13
PL183600B1 (pl) 2002-06-28
NO974453L (no) 1997-11-19
US5552396A (en) 1996-09-03
EA000598B1 (ru) 1999-12-29
HUP9801250A3 (en) 1998-12-28
NZ305276A (en) 1999-02-25
WO1996030048A1 (en) 1996-10-03
EA199700280A1 (ru) 1998-02-26
CN1093767C (zh) 2002-11-06
US5821365A (en) 1998-10-13
MX9707431A (es) 1997-12-31
CA2216535C (en) 2002-05-07
US5624949A (en) 1997-04-29
AU5324996A (en) 1996-10-16
EP0735038A1 (en) 1996-10-02
PL322584A1 (en) 1998-02-02
KR19980703380A (ko) 1998-10-15
US6057440A (en) 2000-05-02
US5719175A (en) 1998-02-17
US5674862A (en) 1997-10-07

Similar Documents

Publication Publication Date Title
HUP9801250A2 (hu) Makrociklusos 3,4-bisz(3,3'-indolil)-pirrolin-2,5-dion-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP9902471A2 (hu) Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP9802694A1 (hu) Benzamidszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
MY136249A (en) Phenylethanolamine compounds as anti-obesity agents
GB9024730D0 (en) Diazine derivatives
HUP0001232A2 (hu) Béta-amiloid peptid kibocsátást és/vagy szintézist gátló cikloalkil-, laktám-, laktonszármazékok, és ezek tio-analógjai, valamint e vegyületeket tartalmazó gyógyászati készítmények
ES8201966A1 (es) Un procedimiento de produccion de derivados de fenetilamina sulfamoil-sustituidos
HUP9900949A2 (hu) Triazolilcsoportot tartalmazó foszfátok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9700992A2 (hu) 3-(Piperid-4-il)-1,2-benzizoxazol- és 3-(piperazin-4-il)-1,2-benzizoxazol-származékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények
HUP9802937A2 (hu) Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
HUP0402225A2 (hu) Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69712084T2 (de) Aminothiazole derivate, ihre herstellung und sie enthaltenden pharmazeutischen zusammensetzungen
HUP9904514A2 (hu) 5H-Pirrolo[2,1-c][1,4]-benzodiazepin-3-karboxamid-származékok, eljárás előállításukra, alkalmazásuk és az azokat tartalmazó gyógyszerkészítmények
HUP9802393A2 (hu) Benzotiazolonszármazékok, alkalmazásuk, az ezeket tartalmazó gyógyszerkészítmények, eljárás a vegyületek előállítására és intermedierjeik
ES8605810A1 (es) Un procedimiento para la preparacion de compuestos de beta-lactama
HUP9901376A2 (hu) 1-Metil-karbapenem-származékok, alkalmazásuk, előállításuk, ezeket tartalmazó gyógyszerkészítmények
RU95106653A (ru) Производные 2-имидазолин-5-онов и 2-имидазолин-5-тионов и фунгицидные композиции на их основе
ES8600261A1 (es) Un compuesto fenoxi
HUP9701660A2 (hu) 10,13,15-trioxa-triciklo[9.2.1.1. 9.6]pentadekanon-származékok, eljárás ezek előállítására, és az e vegyületeket tartalmazó gyógyászati készítmények
TR200001222T2 (tr) Yeni tetrasiklikler, bunların üretimi için işlem ve bu birleşikleri içeren farmasötik preparasyonlar.
MY137475A (en) Chemical compounds.
HUP9802042A2 (hu) Taxoidok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
HUP9903514A2 (hu) Cikloalkilén-lánccal rendelkező új ciklusos vegyületek, eljárás azok előállítására és az azokat tartalmazó gyógyszerkészítmények
HUP0402585A2 (hu) Új benzotiazin- benzotiadiazin-származékok, előállításuk, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
HUP9802518A2 (hu) Szulfonamidcsoporttal szubsztituált benzopiránszármazékok, eljárás előállításukra, gyógyszerként történő alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények